Introduction
Fecal incontinence (FI) is defined as the involuntary loss of solid or liquid feces. FI that is refractory to other treatments can be treated with placement of an Artificial Bowel Sphincter (ABS) such as the Acticon Neosphincter. The Acticon Neosphincter is a solid silicone elastomere that consists of 3 fluid-filled components connected by tubing. The components include a cuff that is implanted around the anal canal, a pressure-regulating balloon that is placed in the space of Retzius, and a control pump which is placed in the labia or scrotum. When the cuff is filled with fluid, it occludes the anal canal. The fluid is transferred from the cuff to the pressure regulating balloon by squeezing the control pump. This al- * Corresponding author. [2] . In a small randomized control trial, 14 patients with refractory FI were assigned to conservative management with medications and biofeedback or placement of an ABS. This study concluded that as compared to baseline, ABS, but not conservative management resulted in significant improvement in continence and quality of life [3] . Additionally, a single-center study was conducted from 1996 to 2010 and included 52 patients with refractory FI who received the Acticon Neosphincter. All of these patients had end stage FI that failed conservative management and pelvic floor training for 1 year. 26 patients (50%) required revision of the device. Indications for revision included device malfunction (leaking cuff or leaking pressure regulated balloon), erosion (erosion of cuff in perineum or erosion of tubing in the groin), pump migration, or pain. Fourteen patients (27%) required explantation of the device. Indications included infection, ineffective device, pain, and erosion of cuff into anal canal. Risk of revision was found to rise to above 80% after 10 years of having the device and risk of explanation nearing 40% over the same time period [4] . The exact nature of our patient's device malfunction is uncertain. It appears that the balloon reservoir was not draining fluid properly and was thus expanding in her abdomen. It is conceivable that over time the balloon hardened and lost some of its elasticity hindering its ability to drain fluid back into the cuff. Additionally, failure of the control pump could result in dysfunctional movement of fluid throughout the device leading to balloon expansion. Last, failure or kinking of the tubing could prevent fluid from draining properly from the balloon back to the cuff and cause expansion of the balloon in the abdomen. All of these possible device malfunctions could explain the patient's worsening FI and hardened, indurated left lower quadrant of her abdomen.
Of note, the FDA recalled the Acticon Neosphincter in 2011 due to failure of the control pump resulting in malfunction of the control pump activation mechanism. At time of recall, 225 were in commerce. As this patient's ABS was placed in 2008, this recall could be relevant to her case and her symptoms could be explained by control pump malfunction.
While the patient is currently experiencing ABS device malfunction, it should be noted that the device had been functioning for 10 years before failure. Given the risk of early revision and over an 80% risk of revision and 40% risk of explantation after 10 years of having device, this appears to be a good result. The exact life expectancy of the Acticon neosphincter is unknown. One study reported that 8 of 17 (47%) of their patients had their original ABS still in place after 5 years while another study had patients with functioning devices for more than 10 years after implantation [5, 6] . 
Conclusion
In conclusion, this case provided an atypical etiology of a left lower quadrant mass secondary to a malfunctioning ABS that was diagnosed on CT ( Figs. 1-5 ).
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